PD-1 blockade is associated with high response rates and durable benefit in patients with relapsed/refractory (R/R) classical Hodgkin lymphoma (cHL) who have relapsed after or are ineligible for autologous hematopoietic cell transplantation (auto-HCT).1⇓⇓⇓-5
Leggi tutto l'articolo sul sito www.bloodjournal.org